Scientists studying the most common and aggressive type of brain tumour in adults have discovered a new way of analysing diseased and healthy cells from the same patient.
Findings from St. Jude Children’s Research Hospital show that cell-free DNA in cerebrospinal fluid can be used to detect measurable residual disease and identify patients at risk of relapse.
The University of Texas MD Anderson Cancer Center celebrates its sixth annual Boot Walk to End Cancer® on Saturday, Nov. 6. Due to ongoing COVID-19 precautions, the 1.2-mile walk will be held virtually to keep participants, their families and their communities safe. Participants are encouraged to walk a personalized route in their own neighborhoods, whether it be on a trail, track or sidewalk. Registration is open at mdanderson.org/bootwalk.
Family traits can be a source of pride – and a source of worry. Fortunately, only 5% to 10% of all cancers can be linked to a genetic mutation passed on from your mom or dad. How can you gauge your genetic risk?
A high-fat diet increases the incidence of colorectal cancer. Cold Spring Harbor Laboratory Fellow Semir Beyaz and collaborators from Harvard Medical School and Massachusetts Institute of Technology have discovered that in mice, fat disrupts the relationship between intestinal cells and the immune cells that patrol them looking for emerging tumors.
Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells, shows a study published today in eLife.
Memorial Sloan Kettering Cancer Center (MSK) today announced a $25 million gift from Louis V. Gerstner, Jr. to create the Louis V. Gerstner, Jr. Physician Scholars Program. Designed to support the innovative research of physician-scientists who are early in their career at MSK, the Gerstner Physician Scholars Program will advance promising scientific research and further the careers of outstanding junior faculty.
Mariah Candelaria is a three-time survivor of Hodgkin Lymphoma and received a stem cell transplant at the University of New Mexico Comprehensive Cancer Center. During and after her recovery she’s leaned on dance to make it through. Now she wants to give back to others who are going through similar challenges fighting cancer.
The National Cancer Institute renewed the “comprehensive” designation of the UC Davis Comprehensive Cancer Center in recognition of its breadth and depth in cancer research, clinical care, cancer control and population sciences.
Hopkins Med News Update
Sanford Burnham Prebys professor Peter D. Adams, Ph.D., and Salk Institute professor Gerald Shadel, Ph.D., have been awarded a grant from the NIH’s National Institute on Aging for $13 million, funding a five-year project to explore the connection between aging and liver cancer.
Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their physical activity and ability to accomplish the basic pursuits of daily life, researchers from The University of Texas
MD Anderson Cancer Center reported today in Cancer.
A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was highly effective in mice implanted with human neuroblastoma tissue.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new method to measure breast cancer response, a new immunotherapy approach for multiple myeloma, characterization of the immune landscape of cholangiocarcinoma, a new contrast agent to improve molecular imaging techniques, and new treatment targets in breast, gynecologic and pancreatic cancers.
The Coriell Institute for Medical Research and Van Andel Institute (VAI) have been awarded a prestigious Specialized Programs of Research Excellence (or SPORE) grant from the National Cancer Institute (award P50CA254897). The five-year grant valued at an estimated $12.4 million will support nearly 20 scientists as they work to improve epigenetic therapies for cancer. The project is co-led by Coriell’s President and CEO Jean-Pierre Issa, MD, Van Andel Institute’s Chief Scientific Officer Peter A. Jones, PhD, DSc (hon), and Johns Hopkins University and VAI’s Stephen Baylin, MD.
The University of New Mexico Comprehensive Cancer Center has once again been awarded the highest designation and rating in the United States for cancer treatment and research programs.
People who have received organ transplants face an elevated risk of developing cancer, primarily due to immunosuppression from medications to prevent organ rejection, as well as underlying medical conditions.
Armando Sardi, M.D., FACS, Medical Director of The Institute for Cancer Care at Mercy and Chief of the Division of Surgical Oncology with Mercy Medical Center in Baltimore, MD, was recently recognized as an Expertscape Expert in Peritoneal Neoplasms.
In human cancer cell and mouse studies, researchers from Johns Hopkins Medicine have found that a set of proteins work in tandem to build supply lines that deliver oxygen and nutrients to tumors, enabling them to survive and grow. The protein twosome, PADI4 and HIF-1, ramp up their activity under low-oxygen conditions that are typically found in a fast-growing tumor, allowing it to build new blood vessels that feed the cancer’s growth.
Here are eight amazing developments in the use of Focused Ultrasound from just the last three months, including: treating cancerous tumours, triggering the targeted release of medicine in the body, immunotherapy, and pain management. See more in the Focused Ultrasound Channel
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer.
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
A new therapeutic era has been ushered in with Adoptive Cell Immunotherapy, which uses patient-harvested T cells genetically engineered against tumor-specific targets.
Every year more than 1.3 million Americans will be living with, or be in remission from, a blood cancer. John Conti, M.D. discusses common symptoms and treatment.
Think of it like radio making way for television. Image-guided radiation therapy has evolved to include the ability to track tumors in real time during treatment. It’s improving cure rates and limiting side effects for a growing number of cancer patients.
Johns Hopkins scientist Ashani Weeraratna, PhD, a leading cancer researcher who specializes in melanoma and the effects of aging on cancer, has been appointed by President Joe Biden to serve as a member of the National Cancer Advisory Board.
Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provides an accurate framework to match patients with non-small cell lung cancer (NSCLC) to the right drugs.
A hallmark of cancer is its ability to replicate, a process commonly driven by the reactivation of the telomerase enzyme complex, which helps prevent the aging and death of healthy cells and keeps stem cells in bone marrow and the intestines from producing normal cells in those organs. When telomerase is activated in cancer cells, it helps them survive and duplicate in the body.
Using a virus that grows in black-eyed pea plants, researchers developed a new therapy that could keep metastatic cancers from spreading to the lungs, as well as treat established tumors in the lungs.
A new study at Tel Aviv University found that eosinophils – a type of white blood cells – are recruited to the battle against cancer metastases in the lungs.
Os pesquisadores da Mayo Clinic biomanufaturaram a terapia de células T receptoras de antígenos quiméricos (terapia celular CAR-T) de uma nova maneira, a fim de rastrear a jornada de combate ao câncer das células e prever efeitos tóxicos colaterais.
Los investigadores de Mayo Clinic manipularon biológicamente y de forma novedosa la terapia de células T con receptor de antígeno quimérico (CAR-T, por sus siglas en inglés) a fin de averiguar cómo es la batalla de las células cancerosas y predecir los efectos secundarios tóxicos.
A new study led by scientists at Sanford Burnham Prebys has shown that the protein RNF5 plays an unusual role in acute myeloid leukemia (AML). Unlike its expected role, marking aberrant proteins for destruction, RNF5 binds with a second cell protein called RBBP4 to control expression of genes implicated in AML. These findings, published in Nature Communications, have important implications for improving AML patient outcomes.
“We were uniquely positioned to take the evidence gleaned from our ongoing effort to address why firefighters are at increased risk of cancer incidence and mortality and rapidly translate it to a disaster that could augment this risk substantially,” said Dr. Kobetz, Sylvester’s associate director for population sciences and cancer disparity and the University of Miami’s vice provost for research and scholarship. “Our hope is that we and our firefighter colleagues learn together how to mitigate the risks that emerge in a different disaster scenario.”
A Ludwig Cancer Research study conducted in both mice and a small group of patients with advanced cancers has shown that so-called “cold” tumors that are nearly devoid of immune cells—and therefore unresponsive to immunotherapy—can be turned “hot” with extremely low doses of radiation and the rational use of existing therapies.
A new study in animal models shows that a cancer tumor alone can lead to cardiac damage, and suggests the culprits are free radicals interacting with cells in the heart. Adding antioxidants to food consumed by fruit flies with tumors reversed the damage to their hearts.
Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different “program” that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at NUS has developed a software called ModTect that can help reveal the relationships between RNA modifications and the development of diseases and disorders. Their work highlights the potential of using RNA modifications as biomarkers to test for diseases.
A preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, led by Qingyun Liu, PhD, has been awarded a nearly $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
The gut microbiome can impact us in a variety of different ways, from our metabolism to our mood. Now, NIBIB-funded researchers are investigating if a fiber-based gel can restore beneficial microbes in the gut to enhance the efficacy of immune checkpoint inhibitors, a type of cancer immunotherapy treatment, in mice.
Hopkins Med News Update
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts.
A chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it, new UBC research has found.
When most people think about cancer, they tend to think of lumps and bumps, something visible they can see and touch. But with blood cancers, there are no immediate visible signs, just the effects of the cancer in the blood system. John Conti, M.D., explains more.
A retrospective analysis of large datasets of biomarkers from tumors and healthy tissue by researchers at the Johns Hopkins Kimmel Cancer Center Convergence Institute suggests that older cancer patients could benefit as much as younger patients from cancer immunotherapies.
St. Jude Children’s Research Hospital scientists have revealed a previously unknown role for CTCF, a pivotal transcription regulator linked to cancer.
Huntsman Cancer Institute melanoma researchers have generated the first “atlas” of human melanocytes located in the body.
New study shows CAR T cells expressing RN7SL1 can activate the body’s natural immune cells against difficult-to-treat cancers
No parent wants to hear the word “cancer.” Fortunately, few will, but it’s always smart to be attuned to signs that might warrant a further look. Two Penn State Health Children’s Hospital doctors discuss the warning signs.
St. Jude Children’s Research Hospital scientists detail how inflammasomes act as integral components of mega-cell death complexes called PANoptosomes for host defense in live viral and bacterial infections.